VENT-03 is under clinical development by Ventus Therapeutics and currently in Phase I for Dermatomyositis. According to GlobalData, Phase I drugs for Dermatomyositis have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VENT-03’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VENT-03 overview
VNX-01 is under development for the treatment of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), dermatomyositis, neuroinflammation, and unspecified rheumatology disorders. It is administered through oral route. The drug candidates are being developed based on structural immunology platform and ReSOLVE drug discovery platform . It acts by targeting CGAS.
Ventus Therapeutics overview
Ventus Therapeutics is a biopharmaceutical firm that develops small molecule therapies to treat autoimmune illnesses, inflammatory diseases, and cancer by targeting the innate immune system. Ventus Therapeutics is headquartered in Waltham, Massachusetts, the US.
For a complete picture of VENT-03’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
